Evidence map›Paper›PMID 27787866›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2017

Podocyte Shape Regulation by Semaphorin 3A and MICAL-1.

Alda Tufro

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Role of Semaphorin 3A in Kidney Development and Diseases.Diagnostics (Basel, Switzerland) · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Alda TufroDepartment of Pediatrics/Nephrology, Cell & Molecular Physiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520-8064, USA. alda.tufro@yale.edu.
Yale University · US

Funding

Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Molecular characterization of a novel cause of human FSGSR01DK109434 · NIDDK · YALE UNIVERSITY · PI TUFRO, ALDA · 2017 to 2020
$2.0M
Function of semaphorin3a in diabetic nephropathyR01DK098824 · NIDDK · YALE UNIVERSITY · PI TUFRO, ALDA · 2013 to 2016
$999k
NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK098824NIDDK NIH HHS R01 DK109434
6 · The paper itself

Abstract

Podocytes are complex epithelial cells with foot processes that are essential for the integrity and function of the kidney glomerular filters. Podocyte foot processes linked by slit diaphragms constitute signaling platforms that tightly regulate the cell shape and the function of the filtration barrier. Semaphorin (Sema) 3A is a class 3 semaphorin secreted by podocytes that has autocrine and paracrine functions in the kidney. We have shown that Sema3A regulates podocyte shape and that excess Sema3A signaling induces glomerular disease and aggravates diabetic nephropathy. MICAL-1 is an actin-binding protein that mediates Sema3A signals in podocytes. This chapter describes the methods used to examine how Sema3A signaling regulates podocyte shape.

Indexed as

Cell ShapeAdaptor Proteins, Signal TransducingAnimalsCalponinsCell LineCell Line, TransformedCytoskeletal ProteinsHumansLIM Domain ProteinsMiceMicrofilament ProteinsMixed Function OxygenasesPodocytesSemaphorin-3AAdaptor Proteins, Signal TransducingCalponinsCytoskeletal ProteinsLIM Domain ProteinsMICAL1 protein, humanMicrofilament ProteinsMixed Function OxygenasesSemaphorin-3AF-actinImmortalized podocytesMICAL-1Sema3AshRNAsiRNAXanthofulvin

Identifiers

PMID27787866
PMCPMC6116512
OpenAlexW2544169847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.